logo
Scientists say it may be possible to protect aging brains from Alzheimer's with an old remedy — lithium

Scientists say it may be possible to protect aging brains from Alzheimer's with an old remedy — lithium

CNN4 days ago
Chronic diseases
Dementia
Getting olderFacebookTweetLink
Follow
In a major new finding almost a decade in the making, researchers at Harvard Medical School say they've found a key that may unlock many of the mysteries of Alzheimer's disease and brain aging — the humble metal lithium.
Lithium is best known to medicine as a mood stabilizer given to people who have bipolar disorder and depression. It was approved by the US Food and Drug Administration in 1970, but it was used by doctors to treat mood disorders for nearly a century beforehand.
Now, for the first time, researchers have shown that lithium is naturally present in the body in tiny amounts and that cells require it to function normally — much like vitamin C or iron. It also appears to play a critical role in maintaining brain health.
In a series of experiments reported Wednesday in the journal Nature, researchers at Harvard and Rush universities found that depleting lithium in the diet of normal mice caused their brains to develop inflammation and changes associated with accelerated aging.
In mice that were specially bred to develop the same kinds of brain changes as humans with Alzheimer's disease, a low-lithium diet revved the buildup of sticky proteins that form plaques and tangles in the brains that are hallmarks of the disease. It also sped up memory loss.
Maintaining normal lithium levels in mice as they aged, however, protected them from brain changes associated with Alzheimer's.
If further research supports the findings, it could open the door to new treatments and diagnostic tests for Alzheimer's, which affects an estimated 6.7 million older adults in the United States, according to the US Centers for Disease Control and Prevention.
The research provides a unifying theory that helps explain so many of the puzzle pieces scientists have been trying to fit together for decades.
'It is a potential candidate for a common mechanism leading to the multisystem degeneration of the brain that precedes dementia,' said Dr. Bruce Yankner, a professor of genetics at Harvard Medical School, who led the study. 'It will take a lot more science to determine whether this is a common pathway… or one of several pathways,' to Alzheimer's, he added. 'The data are very intriguing.'
In an editorial published in Nature, Dr. Ashley Bush, a neuroscientist who directs the Melbourne Dementia Research Center at the University of Melbourne in Australia, said the researchers 'present compelling evidence that lithium does in fact have a physiological role and that normal aging might impair the regulation of lithium levels in the brain.' He was not involved in the study.
Close examination of human and animal brain tissues, along with genetic investigations in the study, found the mechanism that appears to be at play: Beta amyloid plaques — the sticky deposits that gum up the brains of Alzheimer's patients — bind to lithium and hold it, including the type that's normally present in the body, as well as the commonly prescribed form. This binding depletes lithium available for nearby cells, including important scavengers known as microglia.
When the brain is healthy and functioning normally, microglia are waste managers, clearing away beta amyloid before it can accumulate and can cause harm. In the team's experiments, microglia from the brains of lithium-deficient mice showed a reduced ability to sweep away and break down beta amyloid.
Yankner believes this creates a downward spiral. The accumulation of beta amyloid soaks up more and more lithium, further crippling the brain's ability to clear it away.
He and his colleagues tested different lithium compounds and found one — lithium orotate — that doesn't bind to amyloid beta.
When they gave lithium orotate to mice with signs of Alzheimer's in their brains, these changes reversed: Beta amyloid plaques and tangles of tau that were choking the memory centers of the brain were reduced. Mice treated with lithium were once again able to navigate mazes and learn to identify new objects, whereas those who got placebos showed no change in their memory and thinking deficits.
In its natural form, lithium is an element, a soft, silvery-white metal that readily combines with other elements to form compounds and salts. It's naturally present in the environment, including in food and water.
Scientists have never fully known how it works to improve mood — only that it does. The original formula for 7Up soda included lithium — it was called 7Up Lithiated Lemon Soda — and touted as a hangover cure and mood lifter 'for hospital or home use.' Some hot springs known to contain mineral water brimming with lithium became sought out wellness destinations for their curative powers.
Still, people who take prescription doses of lithium — which were much higher than the doses used in the new study — can sometimes develop thyroid or kidney toxicity.
Tests of the mice given low doses of lithium orotate showed no signs of damage.
That's encouraging, Yankner said, but it doesn't mean people should try to take lithium supplements on their own.
'A mouse is not a human. Nobody should take anything based just on mouse studies,' Yankner said.
'The lithium treatment data we have is in mice, and it needs to be replicated in humans. We need to find the right dose in humans,' he added.
The normal amounts of lithium in our bodies, and the concentrations given to the mice, are small — about 1,000 times lower than doses given to treat bipolar disorder, Yankner notes.
Yankner said he hoped toxicity trials of lithium salts would start soon. Neither he nor any of his co-authors have a financial interest in the outcome of the research, he said.
The National Institutes of Health was the major funder of the study, along with grants from private foundations.
'NIH support was absolutely critical for this work,' Yankner said.
The new research corroborates earlier studies hinting that lithium might be important for Alzheimer's. A large Danish study published in 2017 found people with higher levels of lithium in their drinking water were less likely to be diagnosed with dementia compared with those whose tap water contained naturally lower lithium levels. Another large study published in 2022 from the United Kingdom found that people prescribed lithium were about half as likely has those in a control group to be diagnosed with Alzheimer's, suggesting a protective effect of the drug.
But lithium's use in psychiatry caused it to become type cast as therapeutic, Yankner said. No one realized it might be important to the body's normal physiology.
That happened in part because the amounts of lithium that typically circulate in the body are so small, they couldn't be quantified until recently. Yankner and his team had to adapt new technology to measure it.
In the first stage of the research, the scientists tested the brain tissue and blood of older patients collected by the brain bank at Rush University for trace levels of 27 metals. Some of the patients had no history of memory trouble, while others had early memory decline and pronounced Alzheimer's. While there was no change in the levels of most metals they measured, lithium was an exception. Lithium levels were consistently lower in patients with mild cognitive impairment or Alzheimer's compared to those with normal brain function. The brains of patients Alzheimer's disease also showed increased levels of zinc and decreased levels of copper, something scientists had observed before.
Consistently finding lower lithium levels in the brains of people with memory loss amounted to a smoking gun, Yankner said.
'At first, frankly, we were skeptical of the result because it wasn't expected,' said Yankner.
But it held up even when they checked samples from other brain banks at Massachusetts General Hospital, Duke and Washington universities.
'We wanted to know whether this drop in lithium was biologically meaningful, so we devised an experimental protocol where we could take lithium selectively out of the diet of mice and see what happens,' Yankner said.
When they fed the mice a low-lithium diet, simply dropping their natural levels by 50%, their brains rapidly developed features of Alzheimer's.
'The neurons started to degenerate. The immune cells in the brain went wild in terms of increased inflammation and worse maintenance function of the neurons around them, and it looked more like an advanced Alzheimer patient,' Yankner said.
The team also found the gene expression profiles of lithium-deficient mice and people who had Alzheimer's disease looked very similar.
The researchers then started to look at how this drop in lithium might occur. Yankner said in the earliest stages there's a decrease in the uptake of lithium in the brain from the blood. They don't yet know exactly how or why it happens, but it's likely to be from a variety of things including reduced dietary intake, as well as genetic and environmental factors.
The major source of lithium for most people is their diet. Some of the foods that have the most lithium are leafy green vegetables, nuts, legumes and some spices like turmeric and cumin. Some mineral waters are also rich sources.
In other words, Yankner said, a lot of the foods that have already proven to be healthy and reduce a person's risk of dementia may be beneficial because of their lithium content.
'You know, oftentimes one finds in science that things may have an effect, and you think you know exactly why, but then subsequently turn out to be completely wrong about why,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scientists Are Finally Making Progress Against Alzheimer's
Scientists Are Finally Making Progress Against Alzheimer's

Wall Street Journal

time26 minutes ago

  • Wall Street Journal

Scientists Are Finally Making Progress Against Alzheimer's

Buck up, baby boomers. Sixty may not be the new 40, but 80 could soon be the new 60. A trove of new Alzheimer's research suggests that medicines and lifestyle changes can not only slow but prevent, even reverse, the debilitating disease. Alzheimer's is characterized by a buildup of amyloid plaque and tangles of tau proteins in the brain. They trigger inflammation, which in turn causes cognitive decline and neuron death. Scientists don't know exactly what causes this destructive cascade. The disease's complexity stymied the quest for treatments for decades, but no more. Scientists are learning quickly.

Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267
Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267

Yahoo

timean hour ago

  • Yahoo

Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267

UnitedHealth Group Inc. (NYSE:UNH) is one of the best defensive stocks to invest in according to analysts. At the time of writing this article, UnitedHealth ranks among the 10 biggest year-to-date decliners, which have lost over 50% among U.S.-listed stocks with a market capitalization exceeding $2 billion. The company, which was marred by government investigations, operational failures, and leadership changes, reported mixed Q2 2025 earnings results at the end of July. Those results have been unable to shore up the share price, as the long-term growth outlook is still murky. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. The company guided for 2025 adjusted EPS to be over $16, which was significantly below Bloomberg's consensus expectations of $20.4. Seeing the brighter side, Jeff Jonas, portfolio manager at Gabelli Funds, called the guidance highly conservative and believes that it will be easier for the company to beat such low expectations. However, the steep correction and valuation discount have attracted analysts' interest, with around two-thirds of them having a Buy or equivalent rating. One of the analysts who maintains an optimistic view is Wells Fargo's Stephen Baxter. On August 4, Baxter maintained an Overweight rating on UnitedHealth but lowered his price target to $267 from $306. The revision followed a recently held management meeting where he assessed the company's updated outlook. According to the analyst, UnitedHealth's management remains confident in the company's ability to meet its reset 2025 guidance. In his view, management is taking a cautious but disciplined approach in factoring in cost trends and margin recovery. Baxter views this conservatism positively, suggesting it reduces the risk of further downside revisions. UnitedHealth Group Inc. (NYSE:UNH) is a healthcare company that provides health insurance and healthcare solutions in the U.S. and globally under the UnitedHealthcare and Optum brands. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Actor with colorectal cancer shares simple sign that he ignored: ‘I had no idea'
Actor with colorectal cancer shares simple sign that he ignored: ‘I had no idea'

Yahoo

timean hour ago

  • Yahoo

Actor with colorectal cancer shares simple sign that he ignored: ‘I had no idea'

James van der Beek has revealed the first warning sign of his colon cancer — and it's one that did not seem alarming at the time. The "Dawson's Creek" actor, 48, who announced his colorectal cancer diagnosis in November 2024, recently told Healthline that "there wasn't any red flag or something glaring." "I was healthy. I was doing the cold plunge," he said. "I was in amazing cardiovascular shape, and I had stage 3 cancer, and I had no idea." Colorectal Cancer Diagnoses Soar Among Younger Adults For One Key Reason The one symptom that he did experience was a change in bowel movements, which the actor chalked up to an effect of his coffee consumption. "Before my diagnosis, I didn't know much about colorectal cancer," van der Beek said. "I didn't even realize the screening age [had] dropped to 45; I thought it was still 50." Read On The Fox News App He ultimately underwent a colonoscopy, which revealed that the actor had stage 3 colon cancer. Professor Eitan Friedman, M.D., Ph.D., an oncologist and founder of The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center in Israel, confirmed that changes in bowel habits is the primary red flag that should raise the suspicion of colorectal cancer. Others include fatigue as a result of anemia, blood in stool, weight loss, loss of appetite and abdominal discomfort, Friedman, who has not treated van der Beek, told Fox News Digital. Dr. Erica Barnell, M.D., Ph.D., a physician-scientist at Washington University School of Medicine — and co-founder and chief medical officer at Geneoscopy — noted that van der Beek's experience of having no "glaring" signs is common. "Many colorectal cancers develop silently, without obvious symptoms," Barnell, who also did not treat the actor, told Fox News Digital. "By the time symptoms appear, the disease may already be advanced." Symptoms are "especially worrisome" for those 45 and older who have at least one first-degree relative with colon cancer or other GI malignancies, and those with active inflammatory bowel disease, such as ulcerative colitis or Crohn's disease, added Friedman, who is also an advisory board member at SpotitEarly, a startup that offers an at-home breath test to detect early-stage cancer signals. The overall chance of an average-risk person getting colorectal cancer over a lifetime is 4% to 5%, according to Friedman. "Colonoscopy at age 45 onwards, at five- to 10-year intervals, has been shown to lead to early detection of polyps that have the potential to become malignant, and to allow for their removal as an effective means of minimizing the risk of malignant transformation," he said. Click Here To Sign Up For Our Health Newsletter Unfortunately, Barnell noted, "screening compliance in the U.S. remains below national targets, and gaps are widest in rural, low-income and minority communities." To help close those gaps, she called for greater access to "accurate, noninvasive screening technologies," along with efforts to increase public awareness. "Most people don't like talking about bowel habits, but paying attention to changes can save your life," Barnell said. "Screening gives us the chance to find problems early — often before you feel sick — and that can make all the difference." For more Health articles, visit Fox News Digital reached out to van der Beek's representative for article source: Actor with colorectal cancer shares simple sign that he ignored: 'I had no idea' Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store